Company profile
Comera Life Sciences Holdings, Inc.
OTC: CMRA · Healthcare · Biotechnology
#917 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ 30GM —SS 21
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), filing timeliness · ↓ disclosure history, market scale
Methodology →Revenue TTM
$1.0M
Rev growth YoY (TTM)
+81.8%
Net income (FY)
-$18.0M
Employees
12
as of 2026-08-30
Market cap
$3.1k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$633.1k$633.1k2022
Net income-$18.0M-$18.0M2022
Operating income-$12.0M-$12.0M2022
Total assets$3.7M$3.7M2022
Liabilities$5.5M$5.5M2022
Equity-$6.2M-$6.2M2022
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Comera Life Sciences Holdings, Inc.’s revenue?
Comera Life Sciences Holdings, Inc. booked $633.1k in FY2022 revenue, growing 98% year over year — faster than most Healthcare companies we track, at a -2843.8% net margin.
Peers · Healthcare
Polomar Health Services, Inc.28DMarizyme, Inc.——BioXcel Therapeutics, Inc.27DCEN Biotech, Inc.——Co-Diagnostics, Inc.33DNovelStem International Corp.37DNeighbors
Middlesex →Key facts
CEOMichael G. Campbell
SectorHealthcare
IndustryBiotechnology
HeadquartersWoburn, MA
ExchangeOTC: CMRA
Employees12
IPO date2020-12-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.